Immunic Announced The Presentation Of Additional Data From Its Phase 2 CALLIPER Trial Of Lead Asset, Vidofludimus Calcium (IMU-838), For Progressive Multiple Sclerosis At The Americas Committee For Treatment And Research In Multiple Sclerosis Forum 2026
Benzinga Newsdesk 9 months ago
BiotechHealth CareGeneral
Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity.CALLIPER Subset Data Demonstrate Reductions in EBV-Specific T-Cell Receptor Sequences,
- Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity.
- CALLIPER Subset Data Demonstrate Reductions in EBV-Specific T-Cell Receptor Sequences, Underlining Broad-Spectrum Antiviral Effects of Vidofludimus Calcium.